Advertisement

Current Osteoporosis Reports

, Volume 11, Issue 1, pp 11–20 | Cite as

Prostate Cancer and Osteoporosis

  • Stephen P. Tuck
  • Birgit Hanusch
  • Julie Walker
  • Harish K. Datta
Male Osteoporosis (BL Clarke, Section Editor)

Abstract

Adenocarcinoma of the prostate is one of the commonest cancers in the world. Due to a combination of earlier detection and better treatments, survival has increased dramatically. Prostate cancer itself is associated with lower bone density and increased fractures. This is compounded by the use of androgen deprivation therapy, which causes dramatic falls in circulating testosterone and estrogen, resulting in rapid falls in bone density, decreased muscle mass, and increased fracture rates. Bisphosphonates have been demonstrated to prevent and reverse this bone loss, but there are no anti-fracture data. Denosumab, a monoclonal antibody to RANKL, has recently been shown to increase bone density and reduce fracture rates. Prostate cancer also commonly metastasizes to bone where it can cause complications such as fracture and pain. Both zoledronic acid and denosumab have been demonstrated to reduce skeletal related events. Comparative studies would suggest that densosumab may have an advantage over zoledronic acid.

Keywords

Prostate cancer Osteoporosis Fractures Androgen deprivation therapy Treatment 

Notes

Disclosure

The authors reported no potential conflicts of interest relevant to this article.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance•• Of major importance

  1. 1.
    Eble JN, Sauter G, Epstein JI, et al. Pathology and genetics: Tumours of the Urinary system and male genital organs. WHO classification of tumors. Lyon: IARC Press; 2004. p. 160–215.Google Scholar
  2. 2.
    Cancer research UK statistics. Available at: http://info.cancerresearchuk.org/cancerstats/types/prostate/. 2012.
  3. 3.
    Jermal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin. 2006;56:106. 2006.CrossRefGoogle Scholar
  4. 4.
    Huggins C, Hodges CV. Studies on prostate cancer I. The effect of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293.Google Scholar
  5. 5.
    D’Amico AV, Manola J, Loffredo M, et al. 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004;292:821.PubMedCrossRefGoogle Scholar
  6. 6.
    Roach III M, DeSilvio M, Lawton C, et al. Phase III trial comparing whole-pelvic vs prostate only radiotherapy and neoadjuvant vs adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol. 2003;21:1904.PubMedCrossRefGoogle Scholar
  7. 7.
    Pilepich MV, Winter K, John MJ, et al. Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;50:1243.PubMedCrossRefGoogle Scholar
  8. 8.
    Laverdiere J, Nabid A, De Bedoya LD, et al. The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer. J Urol. 2004;171:1137.PubMedCrossRefGoogle Scholar
  9. 9.
    Klotz LH, Goldenberg SL, Jewett MA, et al. Long-term follow up of a randomized trial of 0 vs 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol. 2003;170:791.PubMedCrossRefGoogle Scholar
  10. 10.
    Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92–02. J Clin Oncol. 2003;21:3972.PubMedCrossRefGoogle Scholar
  11. 11.
    Crook J, Ludgate C, Malone S, et al. Report of a multicenter Canadian phase III randomized trial of 3 months vs 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2004;60:15.PubMedCrossRefGoogle Scholar
  12. 12.
    Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet. 2002;360:103.PubMedCrossRefGoogle Scholar
  13. 13.
    Park S, Meng MV, Elkin EP, et al. Androgen deprivation use with external beam radiation for prostate cancer: results from CaPSURETM. J Urol. 2005;174:1802–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Fletcher CDM, Becker AE, Calonje E, et al. Diagnostic histopathology of tumours. London: Churchill Livingston; 2007. p. 755.Google Scholar
  15. 15.
    Young RH, Srigley JR, Amin MB, et al. Tumors of the prostate gland, seminal vesicles, male urethra, and penis. Atlas of tumor pathology 3rd series. Washington DC: AFIP; 2000.Google Scholar
  16. 16.
    Mostofi FK, Sesterman I, Sobin LH, editors. Histological typing of prostate tumors. International classification of tumors. Geneva, Switzerland: World Health Organization. 1980. p. 17–23.Google Scholar
  17. 17.
    Humprey PA. Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol. 2004;17:292–306.CrossRefGoogle Scholar
  18. 18.
    Epstein JI, Allsbrook Jr WC, Amin MB, et al. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostate carcinoma. Am J Surg Pathol. 2005;29:1228–42.PubMedCrossRefGoogle Scholar
  19. 19.
    Bostwick DG. Gleason grading of prostate needle biopsies. Correlation with grade in 316 matched prostatectomies. Am J Surg Pathol. 1994;18:797–803.Google Scholar
  20. 20.
    Stamey TA, McNeal JE, Yemoto CM, et al. Biological determinants of cancer progression in men with prostate cancer. JAMA. 1999;281:1395–400.PubMedCrossRefGoogle Scholar
  21. 21.
  22. 22.
    Mitra A, Fisher C, Foster CS, et al. Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype. Br J Cancer. 2008;98:502–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Eales RA. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet. 2008;40:316–21.CrossRefGoogle Scholar
  24. 24.
    Yeager M, Orr N, Hayes RB, et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet. 2007;39:645–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Parker C, Dearnley D. The role of hormone therapy as a neoadjuvant to radical prostate radiotherapy. Clin Oncol. 2003;15:316–7.CrossRefGoogle Scholar
  26. 26.
    Widmark A, Klepp O, Solberg A, et al. Scandinavian Prostate Cancer Group Study 7; Swedish Association for Urological Oncology 3. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomized phase III trial. Lancet. 2009;373(9660):301–8.PubMedCrossRefGoogle Scholar
  27. 27.
    • Smith MR, McGovern FJ, Falon MA, et al. Low bone mineral density in hormone-naïve men with prostate carcinoma. Cancer. 2001;91:2238. One of the earliest studies to demonstrate low BMD in men with prostate cancer prior to ADT.PubMedCrossRefGoogle Scholar
  28. 28.
    • Hussain SA, Weston R, Stephenson RN, et al. Immediate dual energy X-ray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipulation. BJU Int. 2003;92:690. Another early study to demonstrate low BMD in men with prostate cancer prior to ADT. This time in advanced prostate cancer.PubMedCrossRefGoogle Scholar
  29. 29.
    •• Mistry R, Hughes D, Wadhwa V, Parr N. Lateral spine radiographs before androgen deprivation treatment detect a high incidence of undiagnosed vertebral fragility fractures in men with advanced prostate cancer. J Urol. 2011;186(2):474–80. This study demonstrates a high incidence of vertebral fractures in men with prostate cancer even before ADT. This fact was not previously appreciated.PubMedCrossRefGoogle Scholar
  30. 30.
    Melton III LJ, Lieber MM, Atkinson EJ, et al. Fracture risk in men with prostate cancer: a population-based study. J Bone Miner Res. 2011;26(8):1808–15.PubMedCrossRefGoogle Scholar
  31. 31.
    Nishimura Y, Kato D, Chen SE, et al. Smad5 and DPC4 are key molecules in mediating BMP-2-induced osteoblastic differentiation of the pluripotent mesenchymal precursor cell line C2C12. J Biol Chem. 1998;273(4):1872–979.PubMedCrossRefGoogle Scholar
  32. 32.
    Eastham JA, Truong LD, Rogers E, et al. Transforming growth factor-β1: comparative immunohistochemical localization in human primary and metastatic prostate cancer. Lab Investig. 1995;73:628–35.PubMedGoogle Scholar
  33. 33.
    Sanders N, Chattopadhyay O, Kifor T, et al. Ca 2+-sensing receptor expression and PTHrP secretion in PC38 human prostate cancer cells. Am J Physiol Endocrinol Metab. 2001;281(6):E1267–74.PubMedGoogle Scholar
  34. 34.
    Iwamura M, Abrahamsson PA, Foss KA, et al. Parathyroid hormone-related protein: a potential autocrine growth regulator in human cancer cell lines. Urology. 1994;43(5):675–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Thirunavukkarasu K, Miles RR, Halladay DL, et al. Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-β (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects. J Biol Chem. 2001;276(39):36241–50.PubMedCrossRefGoogle Scholar
  36. 36.
    Brown JM, Vessella RL, Kostenuik PJ, et al. Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. Clin Cancer Res. 2001;7:2977–83.PubMedGoogle Scholar
  37. 37.
    Morony S, Capparelli C, Sarosi I, et al. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res. 2001;61:4432–6.PubMedGoogle Scholar
  38. 38.
    Sieber PR, Keiller DL, Kahnoski RJ, et al. Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. J Urol. 2004;171:2272–6.PubMedCrossRefGoogle Scholar
  39. 39.
    Smith MR, Goode M, Zietman AL, et al. Bicalutamide monotherapy vs leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol. 2004;22:2546–53.PubMedCrossRefGoogle Scholar
  40. 40.
    •• Gennari L, Nuti R, Bilezikian JP. Estrogen in men: effects on bone accrual, maintenance, and prevention of bone loss. Expert Rev Endocrinol Metab. 2006;1:281–95. A useful review of the importance of sex steroids in the maintenance of the male skeletal health.CrossRefGoogle Scholar
  41. 41.
    Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab. 2006;91:1305–8.PubMedCrossRefGoogle Scholar
  42. 42.
    Saigal CS, Gore JL, Krupski TL, et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007;110:1493–500.PubMedCrossRefGoogle Scholar
  43. 43.
    Smith MR. Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer. Drugs Aging. 2003;20:175–83.PubMedCrossRefGoogle Scholar
  44. 44.
    Wiren KM, Zhang X, Chang C, et al. Transcriptional up-regulation of the human androgen receptor by androgen in bone cells. Endocrinology. 1997;138:2291–300.PubMedCrossRefGoogle Scholar
  45. 45.
    Sunyer T, Lewis J, Collin-Osdoby P, Osdoby P. Estrogen's bone-protective effects may involve differential IL-1 receptor regulation in human osteoclast-like cells. J Clin Invest. 1999;103(10):1409–18.PubMedCrossRefGoogle Scholar
  46. 46.
    Smith MR, Saad F, Egerdie B, et al. Sarcopaenia during androgen-deprivation therapy for prostate cancer. J Clin Oncol. 2012;30(26):3271–6.PubMedCrossRefGoogle Scholar
  47. 47.
    •• Alibhai SMH, Gogov S, Allibhai Z. Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review. Crit Rev Oncol Hematol. 2006;60:201–15. This is a useful review of the adverse effects of ADT on men with non-metastatic prostate cancer.PubMedCrossRefGoogle Scholar
  48. 48.
    Berruti A, Dogliotti L, Terrone C, et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol. 2002;167:2361–7.PubMedCrossRefGoogle Scholar
  49. 49.
    Smith MR, Eastham J, Gleason DM, et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men undergoing androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003;169:2008–12.PubMedCrossRefGoogle Scholar
  50. 50.
    •• Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352:154–64. This is a pivotal article that is now much referenced on the risk of fracture attributable to ADT.PubMedCrossRefGoogle Scholar
  51. 51.
    Hatano T, Oishi Y, Furuta A, et al. Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer. BJU Int. 2000;86:449–52.PubMedCrossRefGoogle Scholar
  52. 52.
    Oefelein MG, Ricchuiti V, Conrad W, et al. Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol. 2001;166:1724–8.PubMedCrossRefGoogle Scholar
  53. 53.
    Melton III LJ, Alotham KI, Khosla S, et al. Fracture risk following bilateral orchiectomy. J Urol. 2003;169:1747–50.PubMedCrossRefGoogle Scholar
  54. 54.
    Dickman PW, Adolfsson J, Astrom K, Steineck G. Hip fractures in men with prostate cancer treated with orchiectomy. J Urol. 2004;172:2208–12.PubMedCrossRefGoogle Scholar
  55. 55.
    • Abrahamsen B, Nielsen FM, Eskildsen P, et al. Fracture risk in Danish men with prostate cancer: a nationwide register study. BJUI. 2007;100:749–54. A large scale epidemiology study confirming the high risk of fracture as a result of prostate cancer and its treatment.CrossRefGoogle Scholar
  56. 56.
    • Thorstenson A, Bratt O, Akre O, et al. Incidence of fractures causing hospitlization in prostate cancer patients: results from the population-based PCBaSe Sweden. Eur J Cancer. 2012;48(11):1672–81. Another large scale epidemiology study confirming the high risk of fracture as a result of prostate cancer and its treatment.PubMedCrossRefGoogle Scholar
  57. 57.
    Smith MR, McGovern FJ, Fallon MA, et al. Low bone density in hormone-naïve men with prostate carcinoma. Cancer. 2001;91(12):2238–45.PubMedCrossRefGoogle Scholar
  58. 58.
    Murphy V, Norman AR, Shahidi M, et al. Recovery of serum testosterone after neoadjuvant androgen deprivation therapy and radical radiotherapy in localized prostate cancer. BJU Int. 2006;97:476–9.CrossRefGoogle Scholar
  59. 59.
    Gulley JL, Figg WD, Steinberg SM, et al. A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy. J Urol. 2005;173:1567–71.PubMedCrossRefGoogle Scholar
  60. 60.
    Gulley JL, Aragon-Ching JB, Steinberg SM, et al. Kinetics of serum androgen normalisation and factors associated with testosterone reserve after limited androgen deprivation therapy for non-metastatic prostate cancer. J Urol. 2008;180:1432–7.PubMedCrossRefGoogle Scholar
  61. 61.
    Wilke DR, Parker C, Andonowski A, et al. Testosterone and erectile function recovery after radiotherapy and long-term androgen deprivation therapy with luteinizing hormone–releasing hormone agonists. BJU Int. 2006;97:963–8.PubMedCrossRefGoogle Scholar
  62. 62.
    Planas J, Morote J, Orsola A, et al. The relationship between daily calcium intake and bone mineral density in men with prostate cancer. BJU Int. 2007;99:812–6.PubMedCrossRefGoogle Scholar
  63. 63.
    •• Orwoll E, Ettinger M, Weiss S, et al. Alendronate treatment of osteoporosis in men. N Engl J Med. 2000;343:604–10. The importance of this study is that it was the first reasonably large randomized controlled trial of bisphosphonate treatment for male osteoporosis. It also included a substantial number of men who were hypogonadal and proved that oral alendronic acid improved BMD even in the absence of sex steroids.PubMedCrossRefGoogle Scholar
  64. 64.
    •• Greenspan SL, Nelson JB, Trump DL, Resnick NM. Effect of oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer. Ann Intern Med. 2007;146:416–24. One of the largest and most convincing studies to demonstrate that oral alendronic acid could prevent the bone loss induced by ADT.PubMedGoogle Scholar
  65. 65.
    Pandya MB, Broderick W, Campbell C, et al. J Clin Oncol. 2008;26:1606 [Abstract].Google Scholar
  66. 66.
    •• Michaelson MD, Kaufman DS, Lee H, et al. Randomized control trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol. 2007;25:1038–42. This study showed that an annual infusion of zoledronic acid would be sufficient to improve BMD in men receiving ADT for prostate cancer.PubMedCrossRefGoogle Scholar
  67. 67.
    •• Smith MR, Egerdie B, Hernandez Toniz N, et al. Denosumab in men receiving androgen deprivation therapy for prostate cancer. N Engl J Med. 2009;361:745–55. This study proved that denosumab successfully improves BMD in men on ADT for prostate cancer. It also showed a significant reduction in fracture rates. It is, coincidentally, the largest study to ever be conducted on the treatment of male osteoporosis and to be adequately powered to detect changes in fracture rates.PubMedCrossRefGoogle Scholar
  68. 68.
    • Smith MR, Saad F, Egerdie B, et al. Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer; 36 months data. J Urol. 2009;182(6):2670–5. The 3-year follow up data of Reference 67 confirming that improvements in BMD are continued over 3 years.PubMedCrossRefGoogle Scholar
  69. 69.
    Mundy GR. Metastasis to bone: causes, consequences, and therapeutic opportunities. Nat Rev Cancer. 2002;2:584–93.PubMedCrossRefGoogle Scholar
  70. 70.
    Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350:1655–64.PubMedCrossRefGoogle Scholar
  71. 71.
    Shiozawa Y, Pedersen EA, Havens AM, et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest. 2011;121:1298–312.PubMedCrossRefGoogle Scholar
  72. 72.
    Jung Y, Wang J, Song J, et al. Annexin II expressed by osteoblasts and endothelial cells regulates stem cell adhesion, homing, and engraftment following transplantation. Blood. 2007;110:82–90.PubMedCrossRefGoogle Scholar
  73. 73.
    Shiozawa Y, Havens AM, Jung Y, et al. Annexin II/annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer. J Cell Biochem. 2008;105(2):370–80.PubMedCrossRefGoogle Scholar
  74. 74.
    Lu Y, Chen Q, Corey E, et al. Activation of MCP-1/CCR2 axis promotes prostate cancer growth in bone. Clin Exp Metastasis. 2009;26(2):161–9.PubMedCrossRefGoogle Scholar
  75. 75.
    Loberg RD, Ying C, Craig M, et al. CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia. 2007;9(7):556–62.PubMedCrossRefGoogle Scholar
  76. 76.
    Li X, Loberg R, Liao J, et al. A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone. Cancer Res. 2009;69(4):1685–92.PubMedCrossRefGoogle Scholar
  77. 77.
    Chen G, Siccar K, Aprikian A, et al. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer. 2006;107:289–98.PubMedCrossRefGoogle Scholar
  78. 78.
    • Luo JL, Tan W, Ricono JM, et al. Nuclear cytokine-activated 1Kka controls prostate cancer metastasis by repressing. Maspin Nat. 2007;446:690–4. The interesting aspect to this paper is that it shows the importance of high levels of RANKL in the development of bone metastases. It therefore provides a rationale for the use of denosumab.CrossRefGoogle Scholar
  79. 79.
    Guise TA, Mohammad KS, Clines G, et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res. 2006;12:6213s–6s.PubMedCrossRefGoogle Scholar
  80. 80.
    Kingsley LA, Fournier PG, Chirgwin JM, Guise TA. Molecular biology of bone metastasis. Mol Cancer Ther. 2007;6:2609–17.PubMedCrossRefGoogle Scholar
  81. 81.
    Saad F, Lipton A, Cook R, et al. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer. 2007;110:1860–7.PubMedCrossRefGoogle Scholar
  82. 82.
    Saad F, Gleason DM, Murry R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94:1458–68.PubMedCrossRefGoogle Scholar
  83. 83.
    Fizazi K, Lipton A, Mariette X, et al. Randomized Phase II Trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol. 2009;27:1564–71.PubMedCrossRefGoogle Scholar
  84. 84.
    •• Fizazi K, Carducci M, Smith M, et al. Denosumab vs zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomized, double-blind study. Lancet. 2011;377:813–22. This study is important because it is well designed, large, and provides convincing data that these treatments prevent skeletal related events. It also suggests that denosumab may be better than zoledronic acid.PubMedCrossRefGoogle Scholar
  85. 85.
    Coleman R, Gnant M, Morgon G, Clezardin P. Effects of bone-targeted agents on cancer progression and mortality. JNCI. 2012;104:1059–67.PubMedCrossRefGoogle Scholar
  86. 86.
    Gnant M, Clézardin P. Direct and indirect anticancer activity of bisphosphonates: A brief review of published literature. Cancer Treat Rev. 2012;38:407–15.PubMedCrossRefGoogle Scholar
  87. 87.
    Planas J, Trilla E, Raventos C, et al. Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopaenia or osteoporosis. BJU. 2009;104(11):1637–40.CrossRefGoogle Scholar
  88. 88.
    Bruder JM, Ma JZ, Wing N, et al. Effects of alendronate on bone mineral density in men with prostate cancer treated with androgen deprivation therapy. J Clin Densitom. 2006;9(4):431–7.PubMedCrossRefGoogle Scholar
  89. 89.
    Taxel P, Dowsett R, Richter L, et al. Risedronate prevents bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer. BJU Int. 2010;106(10):1473–6.PubMedCrossRefGoogle Scholar
  90. 90.
    Ishizaka K, Machida T, Kobayashi S, et al. Preventative effect of risedronate on bone loss in men receiving androgen-deprivation therapy fpr prostate cancer. Int J Rol. 2007;14(12):1071–5.CrossRefGoogle Scholar
  91. 91.
    Izumi K, Mizokami A, Sugimoto K, et al. Risedronate recovers bone loss in patients with prostate cancer undergoing androgen-deprivation therapy. Urology. 2009;73(6):1342–6.PubMedCrossRefGoogle Scholar
  92. 92.
    Ryan CW, Huo D, Demers LM, et al. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol. 2006;176(3):972–8.PubMedCrossRefGoogle Scholar
  93. 93.
    Israeli RS, Risenberg SJ, Saltzein DR, et al. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy. Clin Genitourin Cancer. 2007;5(4):271–7.PubMedCrossRefGoogle Scholar
  94. 94.
    Satoh T, Kimura M, Matsumoto K, et al. Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naïve prostate carcinoma. Cancer. 2009;115(15):3468–74.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Stephen P. Tuck
    • 1
    • 2
  • Birgit Hanusch
    • 2
  • Julie Walker
    • 2
  • Harish K. Datta
    • 1
  1. 1.Musculoskeletal Research Group, Institute of Cellular MedicineNewcastle UniversityNewcastle upon TyneUK
  2. 2.James Cook University HospitalMiddlesbroughUK

Personalised recommendations